Rocket Pharmaceuticals, Inc.

NasdaqGM:RCKT Stock Report

Market Cap: US$350.6m

Rocket Pharmaceuticals Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

NasdaqGM:RCKT Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
02 Jan 26BuyUS$34,400Elisabeth BjorkIndividual10,000US$3.44
18 Nov 25SellUS$18,721Gaurav ShahIndividual6,276US$2.98
18 Nov 25SellUS$3,240John MilitelloIndividual1,086US$2.98
18 Nov 25SellUS$7,592Jonathan SchwartzIndividual2,545US$2.98
18 Nov 25SellUS$4,910Martin WilsonIndividual1,646US$2.98
27 Aug 25BuyUS$34,100Elisabeth BjorkIndividual10,000US$3.41
19 Aug 25SellUS$4,839Martin WilsonIndividual1,592US$3.07
19 Aug 25SellUS$3,224John MilitelloIndividual1,060US$3.07
19 Aug 25SellUS$7,561Jonathan SchwartzIndividual2,485US$3.07
14 Aug 25SellUS$36,557Martin WilsonIndividual12,109US$3.02
14 Aug 25SellUS$21,263John MilitelloIndividual7,043US$3.02
14 Aug 25SellUS$33,695Jonathan SchwartzIndividual11,161US$3.02
03 Jul 25SellUS$4,257Aaron OndreyIndividual1,477US$2.88
20 May 25SellUS$3,784Martin WilsonIndividual587US$6.45
20 May 25SellUS$14,523Gaurav ShahIndividual2,253US$6.45
20 May 25SellUS$2,301John MilitelloIndividual357US$6.45
20 May 25SellUS$4,944Kinnari PatelIndividual767US$6.45
20 May 25SellUS$5,163Jonathan SchwartzIndividual801US$6.45
16 May 25SellUS$6,175Martin WilsonIndividual946US$6.53
16 May 25SellUS$23,638Gaurav ShahIndividual3,621US$6.53
16 May 25SellUS$4,276John MilitelloIndividual655US$6.53
16 May 25SellUS$10,327Jonathan SchwartzIndividual1,582US$6.53
16 May 25SellUS$9,198Kinnari PatelIndividual1,409US$6.53
22 Apr 25SellUS$5,139John MilitelloIndividual718US$7.16
10 Apr 25BuyUS$101,600Gaurav ShahIndividual20,000US$5.08
09 Apr 25BuyUS$99,165Kinnari PatelIndividual21,099US$4.70
04 Apr 25SellUS$39,647Aaron OndreyIndividual7,489US$5.29
25 Feb 25SellUS$69,109Jonathan SchwartzIndividual6,532US$10.58
21 Feb 25SellUS$34,089Martin WilsonIndividual3,222US$10.58
21 Feb 25SellUS$172,486Gaurav ShahIndividual16,303US$10.58
21 Feb 25SellUS$28,957John MilitelloIndividual2,737US$10.58
21 Feb 25SellUS$64,305Kinnari PatelIndividual6,078US$10.58

Insider Trading Volume

Insider Buying: RCKT insiders have sold more shares than they have bought in the past 3 months.

Ownership Breakdown

What is the ownership structure of RCKT?
Owner TypeNumber of SharesOwnership Percentage
Private Companies104,9270.097%
Individual Insiders2,809,9432.6%
General Public6,130,7215.66%
Hedge Funds26,156,11624.2%
Institutions73,020,52167.5%

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Top Shareholders

Top 25 shareholders own 76.4% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
16.3%
RTW Investments, LP
17,687,772US$57.3m0%0.65%
7.9%
The Vanguard Group, Inc.
8,544,423US$27.7m24%no data
7.82%
Maverick Capital, Ltd.
8,468,344US$27.4m1.25%0.34%
6.57%
BlackRock, Inc.
7,110,092US$23.0m-4.29%no data
3.61%
MPM BioImpact LLC
3,903,381US$12.6m0.01%1.18%
3.55%
Suvretta Capital Management, LLC
3,843,333US$12.5m-7.24%0.33%
3.3%
Millennium Management LLC
3,570,391US$11.6m52%0.01%
2.75%
Morgan Stanley
2,973,061US$9.6m35.4%no data
2.67%
Monaco Asset Management S.A.M.
2,892,261US$9.4m539%2.69%
2.31%
Newtyn Management, LLC
2,502,863US$8.1m25.1%0.7%
2.02%
D. E. Shaw & Co., L.P.
2,189,750US$7.1m121%0.01%
1.77%
Geode Capital Management, LLC
1,914,554US$6.2m-5.73%no data
1.66%
Two Sigma Advisers, LP
1,795,751US$5.8m20.5%0.01%
1.61%
State Street Global Advisors, Inc.
1,745,310US$5.7m-10.2%no data
1.54%
Citadel Advisors LLC
1,670,927US$5.4m971%no data
1.54%
JPMorgan Chase & Co.
1,667,307US$5.4m119%no data
1.49%
Two Sigma Investments, LP
1,609,682US$5.2m-6.7%0.01%
1.21%
Balyasny Asset Management L.P.
1,313,737US$4.3m897%0.01%
1.17%
Prosight Management, LP
1,267,965US$4.1m-19.8%0.79%
1.09%
Gaurav Shah
1,184,534US$3.8m-0.53%no data
0.99%
The Goldman Sachs Group, Inc.
1,071,752US$3.5m0%no data
0.98%
T. Rowe Price Group, Inc.
1,061,295US$3.4m-3.5%no data
0.94%
Qube Research & Technologies Ltd
1,014,358US$3.3m-34.5%no data
0.79%
Tang Capital Management, LLC
850,000US$2.8m0%0.08%
0.77%
AQR Capital Management, LLC
834,252US$2.7m10.5%no data

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/02/12 07:51
End of Day Share Price 2026/02/12 00:00
Earnings2025/09/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Rocket Pharmaceuticals, Inc. is covered by 23 analysts. 12 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jason ZemanskyBofA Global Research
Whitney IjemCanaccord Genuity
Joshua SchimmerCantor Fitzgerald & Co.